HIV and mitochondrial toxicity in children

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 8-12

  Foster, Caroline ^a   Lyall, Hermione ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Children; DNA polymerase ; HIV; Mitochondrial DNA; Nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; ENFUVIRTIDE; LAMIVUDINE; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CHILDHOOD DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA SYNTHESIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECG ABNORMALITY; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL TOXICITY; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRENATAL DRUG EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THIRD TRIMESTER PREGNANCY;

ANTI-HIV AGENTS; CHILD; DISEASE TRANSMISSION, VERTICAL; DNA REPLICATION; DNA, MITOCHONDRIAL; FEMALE; HIV INFECTIONS; HUMANS; MITOCHONDRIAL DISEASES; POINT MUTATION; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 37549030898     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm411     Document Type: Article

References (48)

1. Gibb DM, Duong T, Tookey PA et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327: 1019-21.
2. McComsey G, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004; 18: 1753-68.
3. Gang Y, Hansson GK, Holme E. Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 1992; 71 1268-76.
4. Perry SW, Norman JP, Litzburg A et al. HIV-1 transactivator of transcription protein induces mitochondrial hyperpolarization and synaptic stress leading to apoptosis. J Immunol 2005; 174: 4333-44.
5. Arnaudo E, Dalakas M, Shanske S et al. Depletion of mitochondrial, DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-10.
6. Nolan D, Mallal S. Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms. Antivir Ther 2005; 10: M53-64.
7. Blanche S, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9.
8. Joint United Nations Programme on HIV/AIDS. Report on the Global HIV/ AIDS Epidemic. UNAIDS 2006. http://www.unaids.org://www.tinaids.org www.unaids.org (11 September 2007, date last accessed).
9. Connor EM, Mofenson LM. Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: Pediatric AIDS Clinical Trials Group Protocol 076 - results and treatment recommendations. Pediatr Infect Dis J 1995; 14: 536-41.
10. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochem Biophys Acta 2006; 1757: 700-7.
11. Kohler J, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007; 48: 166-72.
12. Larsen NB, Rasmussen M, Rasmussen LJ. Nuclear and mitochondrial DNA repair: Similar pathways? Mitochondrion 2005; 5: 89-108.
13. Maagard A, Holberg-Petersen M, Kvittingen EA et al. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients. HIV Med 2006; 7: 53-8.
14. Lewis W, Kohler JJ, Hosseini SH et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: Evidence supporting the DNA pol γ hypothesis. AIDS 2006; 20: 675-84.
15. Lewis W, Hasse CP, Miller YK et al. Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS. Lab Invest 2005; 85: 972-81.
16. Miro O, Lopez S, Rodriguez de la Concepcion M et al. Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine. J Acquir Immune Defic Syndr 2004; 37: 1550-5.
17. Lo C, Kazemi MR, Hsue PY et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005; 41: 1341-2.
18. Kakunda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
19. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse transcriptase inhibitors. AIDS 2002; 16: 2165-73.
20. Foster CJ, Lyall EGH. Preventing mother to child transmission of HIV-1. Paediatr Child Health 2007; 17: 126-31.
21. Walker DM, Poirier MC, Campen MJ et al. Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3′-azido-3′-deoxythymidine. Cardiovasc Toxicol 2004; 4: 133-53.
22. Gerschenson M, Nguyen V, Ewings EL et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004; 20 91-100.
23. Divi RL, Leonard SL, Kuo MM et al. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus palas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 2005; 5: 333-46.
24. Lipshultz SE, Easley KA, Orav EJ et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000; 343: 759-66.
25. Divi RL, Leonard SL, Kuo MM et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2007; 48: 201-9.
26. Shiramizu B, Shikuma KM, Kamemoto L et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32: 370-4.
27. Poirier MC, Divi RL, Al-Harthi L et al. Women and Infants Transmission Study (WITS) Group. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33: 175-83.
28. Barret B, Tardieu M, Rustin P et al. For the French Perinatal Cohort Study Group. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-85.
29. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States Cohorts. J Acquir Immune Defic Syndr 2000; 25: 261-8.
30. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380-7.
31. Brogly SB, Ylitato N, Mofenson LM et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21: 929-38.
32. Giaquinto C, De Romeo A, Giacomet V et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15: 1074-5.
33. Alimenti A, Burdge DR, Ogilvie GS et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22: 782-9.
34. Bunders M, Thorne C, Newell ML; European Collaborative Study. Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers. AIDS 2005; 19: 1071-9.
35. Venhoff N, Walker UA. Mitochondrial disease in the offspring as a result of antiretroviral therapy. Expert Opin Drug Saf 2006; 5: 373-81.
36. Hankin CD, Newell ML, Tookey P. Long-term follow-up of uninfected children born to HIV-infected women and exposed to antiretroviral therapy: Survey of parents' and health professionals' views. AIDS Care 2007; 4: 482-6.
37. Haugaard SB, Andersen O, Madsbad S et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 2005; 77: 29-38.
38. Maagaard A, Holberg-Petersen M, Kollberg G et al. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006; 11: 601-8.
39. Walker UA, Bauerle J, Laguno M et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311-7.
40. Montaner JS, Cote HC, Harris M et al. Mitochondrial toxicity in the era of HAART: Evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34 Suppl 1: S85-90.
41. McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19: 15-23.
42. Dwyer DE, Workman C, Hales G et al.; Alliance Study Group. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study. Antivir Ther 2006; 11: 409-19.
43. Fraaij PL, Neubert J, Bergshoeff AS et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 2004; 9: 297-9.
44. El-Sadr WM, Lundgren JD, Neaton JD et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2359-61.
45. Mussini C, Pinti M, Bugarini R et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: A prospective study. AIDS 2005; 19: 1627-33.
46. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18: 1443-51.
47. Cossarizza A, Pinti M, Moretti L et al. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis 2002; 185: 299-305.
48. Vigano A, Pinti M, Nasi M et al. Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: The role of age. J Allergy Clin Immunol 2001; 108: 439-45.